Protocol Ledger

NCT06493578 · Phase II · TERMINATED

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

Interventional Phase II clinical trial protocol NCT06493578 sponsored by Vyne Therapeutics in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-04 Enrollment: 205 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06493578
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)205 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06493578
Protocol FieldVerified Registry Value
NCT IdentifierNCT06493578
Consolidated Lead SponsorVyne Therapeutics
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment205 participants (ACTUAL)
Registered Start Date2024-06-04
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06493578
Hospital Research SiteLocationSite Profile
California Dermatology & Clinical Research InstituteEncinitas, CAOpen Hospital Dossier ->
Center for Dermatology Clinical Research, Inc.Fremont, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI